Adding tucatinib (Tukysa, Seagen) to trastuzumab emtansine (Kadcyla, T-DM1, Genentech) improved progression-free survival (PFS) in patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including those with brain metastases. This news, from the phase 3 HER2CLIMB-02 trial, was presented at the 2023 San Antonio Breast Cancer Symposium (abstract GS01-10).
“This is the second randomized study which included patients with brain metastases to demonstrate that a
FEBRUARY 19, 2024